While we selected T1D as the disease model and insulin as the output for the proof-of-concept study, the gluconate-actuated genetic switch should be readily adaptable to control in situ production and dosing of other therapeutic proteins for the treatment of a wide range of chronic diseases. The gene discussed is INS; the disease is type 1 diabetes mellitus.